Health Care • Biotechnology: Pharmaceutical Preparations
$3.12 ▼ -0.18
(-5.45%)
MKT CAP: $114.7M • VOL: 140.7K
52W L $2 52W H $5
ROARABLE / RQD
E • 32/100
PIOTROSKI
3 / 9
ANIX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-10-31 | FY 2024
FILED 2024-10-31 | FY 2023
FILED 2023-10-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $210.0K | $210.0K |
| YoY Revenue Growth % | — | 0.0% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$11.7M | -$13.8M | -$11.0M |
| Operating Margin % | — | -80.0% | -80.0% |
| Net Income (GAAP) | -$10.9M | -$12.6M | -$9.8M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$7.2M | -$7.3M | -$6.2M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$7.2M | -$7.3M | -$6.2M |
| FCF Margin % | — | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $1.5M | $1.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $15.1M | $17.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ANIX.